Pharmaceutical Technology on MSN
Congruence secures $39.5M to advance small molecule correctors pipeline
The investment will fund the Phase I/Ib study of CGX-926 for MC4R-deficient genetic obesity in healthy subjects and patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results